Establishment of in vitro selection system by multi anti-HIV drugs

2014 Fiscal Year Final Research Report

• Project/Area Number: 24590199
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: National Institute of Infectious Diseases (2012, 2014); The University of Tokyo (2013)
• Principal Investigator: HARADA Shigeyoshi 国立感染症研究所, その他部局等, 主任研究官 (30508643)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: HIV / AIDS / 抗HIV療法 / 薬剤耐性 / 耐性誘導 / 臨床分離株

Outline of Final Research Achievements

The aim of study was to develop an in vitro selection system using human immunodeficiency virus type 1 (HIV-1) by multi anti-HIV drugs. In this study, we determined that (i) the HIV integrase inhibitor raltegravir (RAL)-resistant clone became highly sensitive to the CCR5 antagonist maraviroc (MVC) and (ii) MVC-resistant clone became highly sensitive to the anti-envelope (Env) neutralizing antibodies, respectively.
Furthermore, using established this system, it was determined that acquisitions of resistance mutations were significantly decreased during in vitro selection by multi anti-HIV drugs rather than only single drugs. Thus, this novel system is indicated a useful tool for investigating the compatibility of combined anti-retroviral therapy.

Free Research Field

HIV感染症